GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. But that dream appeared to die this morning as the pharma closed the last programs related to this ...
Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with a variety of frontotemporal dementia (FTD). In the pivot away from ...
GSK Plc is planning five simultaneous late-stage trials for a cancer drug it hopes will be a blockbuster, as new Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results